Empresas do Estado cortam mais de 5 mil milhões à dívida

[C0rr3i4]

...

[C0rr3i4]

A ThromboGenics passará a estar incluída no BEL20, a partir de 18 de Março.

Sector
Healthcare
Biotechnology / Pharmaceuticals
Biotechnology / Pharmaceuticals
Biotechnology

Business Summary
ThromboGenics specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows:
- sales of licenses (96.9%);
- royalties (1.8%);
- other (1.3%).

4-traders.com